Please login to the form below

Not currently logged in

Ex-Pfizer and AZ employees launch start-ups at BioCity Nottingham

European bioscience business centre also appoints Louis Nisbet as chairman

Former AstraZeneca and Pfizer employees have launched new ventures at BioCity Nottingham.

One of Europe's largest bioscience business centres, BioCity will add to its ranks six new companies formed by ex-AZ employees that are set to create 15 new jobs by the end of November.

The centre has also confirmed its virtual tenant drawn from scientists leaving Pfizer's research base in Sandwich, Kent.

AstraZeneca's UK research site at Charnwood in Leicestershire will soon close with the loss of 1,200 jobs and Pfizer said 2,400 jobs would go following the closure of its Sandwich, Kent facility, though some of these have now been spared.

New chairman for BioCity

Meanwhile, BioCity has appointed Louis Nisbet as chairman.

Nisbet, whose early R&D career included spells at Roche, Glaxo and Smith Kline, will oversee the expansion of BioCity services to cater for the increasing demand from both UK and international tenants.

Nisbet said: “I believe BioCity's strong reputation puts us in a unique position to respond to the growing demand for highly-specialised facilities, support services and funding. Life science and bioscience companies wanting to grow need early stage venture capital but this is presently scarce.

“We will be looking to work with our clients and the large pharmaceutical companies, as well as private investors, to find innovative solutions to facilitate partnerships and financing which suit everyone.”

BioCity Nottingham is currently home to nearly 70 companies, including R&D and business support services.

25th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...